A nationwide study in Norway found a 11% increase in type 1 diabetes incidence in children aged 0.5-5 years after the introduction of the rotavirus vaccine in September 2014. However, secondary analyses suggest that the vaccine may not be the cause of this increase.
A new study has found that very low carbohydrate diets may be associated with improved health benefits in children with type 1 diabetes, including better blood sugar control and reduced insulin needs, without negatively impacting growth or increasing acute complications. However, more research is needed to determine the optimal carbohy...
CBL-514 selectively induces apoptosis of fat cells, reducing subcutaneous and visceral fat volume by 10.45% and 22.21% respectively in phase 2 clinical trials. The drug was well-tolerated with mostly mild-to-moderate injection-site reactions.
A European study across eight countries confirms that screening for type 1 diabetes can be effectively implemented in children, with early detection associated with clinical benefits including reduced risk of diabetic ketoacidosis. The study's findings support the integration of screening for early-stage T1D in standard medical care ac...
Researchers found that a low-energy diet combined with structured exercise can reverse early onset type 2 diabetes in approximately half of participants. The study, which included 96 participants aged 18-45, showed significant improvements in blood sugar control, fitness, and muscle mass.
The ACHIEVE-4 study shows orforglipron pills offer superior weight loss and blood sugar control compared to insulin glargine, but with a higher gastrointestinal adverse event rate. Non-inferiority for cardiovascular safety and superiority for weight reduction were demonstrated.
Real-world study data from Germany, Austria and Luxembourg show that GLP-1 receptor agonist drugs improve weight (37% reduction ≥ 5%), blood sugar control (glycaemic improvement) and systolic blood pressure in children and adolescents with type 2 diabetes. These benefits remained significant after adjustment for other factors.
Researchers found trevogrumab significantly reduced lean mass loss by 50% when used with semaglutide. Participants who received trevogrumab experienced a mean increase in lean mass of +0.4%, while those who received placebo experienced a mean decrease of -2.4%.
Mauritius has systematically monitored type 2 diabetes using the 2-hour oral glucose tolerance test, showing a 61% increase in prevalence between 1987 and 2009, but a 11% decrease between 2009 and 2021. The country's multisectoral approaches to prevention and management may hold the key to reversing the epidemic, according to the study.
The phase 2b study evaluates the safety and efficacy of eloralintide in combination with tirzepatide, resulting in substantial weight loss and improvements in blood sugar control. The study demonstrated substantial weight loss and reduction in glycated haemoglobin (HbA1c) across different dosing combinations.
Petrelintide, an amylin-based obesity drug, shows significant weight loss of over 10% in a phase 2 trial, with fewer gastrointestinal side effects compared to GLP-1 drugs. The study also reveals improvements in key cardiovascular risk factors, such as blood pressure and lipid parameters.
Women are more likely to experience weight loss and improved blood sugar control with GLP-1 RAs, but face higher rates of side effects and unequal access to treatment worldwide. Extensive research is needed to address these disparities and optimize treatment for women in various domains.
A systematic review of 43,000 women with diabetes exposed to GLP-1 RAs found no significant associations with preterm birth, stillbirth, or neonatal death, but evidence gaps remain for early pregnancy loss and postpartum use. Further research is needed to address these gaps and provide clearer evidence for women with diabetes
Retatrutide demonstrates substantial weight loss and improved blood sugar control in adults with overweight and type 2 diabetes, with 47% of participants losing at least 20% of their starting weight. The treatment also improves cardiometabolic risk factors and reduces inflammation.
A regulator-mandated study found no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden, and Norway. The study, funded by Novo, included over 97,000 semaglutide users and compared them to users of other non-incretin antidiabetic drugs.
A study of 57,611 UK Biobank participants found that fluctuations in blood pressure were associated with a higher risk of death and strokes. The study suggests that blood pressure variability could help identify high-risk patients, but more research is needed to prove its benefits.
A new AI-based tool uses speech analysis to detect type 2 diabetes in just 20 seconds, with high accuracy rates. The model performed well across different sexes and ages, but had lower performance on recordings from Black participants and those with heart disease, high blood pressure, or obesity.
A study of 2 million adults in Ontario, Canada, found that moving from a high-poverty to a lower poverty neighbourhood significantly lowers the risk of developing type 2 diabetes. Individuals who moved experienced a 57% lower risk compared to those who remained in the same high-poverty area.
A Danish study suggests that GLP-1 drugs could protect heart health in millions of people with overweight. The research found that individuals with a BMI of 25-26.9 and high remnant cholesterol and/or low-grade inflammation have a similar risk of coronary heart disease as those eligible for GLP-1 RAs for weight loss.
Researchers found a 44% lower risk of death from any cause after one year and 35% lower risk after two years among type 2 diabetes patients starting continuous glucose monitoring. CGM use also showed a reduced risk of cardiovascular events, including heart attack and stroke.
Researchers have identified a unique 'bacterial signature' that flags individuals at risk of type 2 diabetes, even if their blood sugar levels are normal. The study analyzed data from over 200,000 adults and found that changes in the gut microbiome can be detected before the onset of diabetes.
A new study found that consuming red meat linked to a 63% higher risk of developing type 2 diabetes due to Neu5Gc, a non-human sugar found in red meat. Higher levels of Neu5Gc were associated with greater risk, even after adjusting for other factors.
A small study of 22 healthy medical students found significant increases in blood sugar levels during exams and the days leading up to them. The study suggests that prolonged exposure to examination stress may have a negative impact on metabolic health.
A new post-hoc analysis of the ATTAIN-1 and -2 studies found significant and similar weight reductions for women of different menopausal status, with up to 14% body weight loss and 12.5cm waist circumference reduction
A study of over 6 million people found that individuals diagnosed with type 2 diabetes before the age of 20 were more likely to have ADHD (14%) and autism (5.7%) compared to those without T2D. This suggests that healthcare systems may need to consider the needs of neurodivergent people when providing care for early-onset T2D.
A new study suggests that eating a diet low in ultra-processed foods and exercising regularly can reduce the risk of type 2 diabetes, even in those with a strong genetic predisposition. The analysis of data on tens of thousands of people found that those who followed these habits were up to 70% less likely to develop the condition.
A study of 1.6 million patients found that the risk of developing chronic kidney disease or heart failure increases substantially over time after a type 2 diabetes diagnosis. Early, proactive management is crucial to reduce the risk of serious complications.
A nationwide study in Denmark found that cancer incidence is 12% higher among men with type 2 diabetes and 22% higher among women with type 2 diabetes compared to those without diabetes. Obesity-related cancers, such as colorectal and postmenopausal breast cancer, are particularly prevalent among people with type 2 diabetes.
Researchers assessed glucose levels, carbohydrate intake, and continuous glucose monitoring accuracy during the 2025 Poznań Marathon. Participants with type 1 diabetes completed the race with performance comparable to controls, highlighting the potential for safe marathon participation with proper glucose management.
A small study using continuous glucose monitoring devices found that sex is not associated with an increased risk of hypoglycaemia in adults with type 1 diabetes. The study's results suggest that blood sugar responses are bidirectional and influenced by pre-SI glucose level, BMI, and time of day.
A UK Biobank study found that higher levels of moderate-to-vigorous physical activity are associated with a substantially lower risk of developing type 2 diabetes, particularly among younger adults. Encouraging older adults to be physically active could prevent more cases of type 2 diabetes due to their high overall risk.
The EASD has published its first evidence-based clinical practice guideline on diabetes distress, emphasizing the importance of assessing and managing emotional burdens in adults with type 1 and type 2 diabetes. The guideline aims to improve clinical care and outcomes by incorporating a person-centered approach to diabetes care.
A new study suggests that individuals with diabetes who focus on tightly controlling their blood sugar levels may be missing out on enjoyable activities due to the associated burden. Higher glucose variability and better sleep quality on the previous day were associated with improved quality of life on the following day.
Researchers discovered a lower risk of subsequent type 1 diabetes development among individuals under 30 who had COVID-19, especially among unvaccinated individuals. The study found a 16% reduced risk across all variants combined and a 42% lower risk 31-180 days post-infection.
Women with a history of gestational diabetes in pregnancy are at a substantially increased risk of developing type 2 diabetes later in life, with a median onset age 13 years earlier than those without prior gestational diabetes. They also experience more severe disease, requiring insulin treatment more frequently.
A 10-fold increase in new case rate of type 2 diabetes in young people under 20 years old since the turn of century has led to a significant shift in the disease's demographics. The study found an accelerating trend in type 2 diabetes incidence, with a 3.8% annual increase between 2002 and 2023.
Researchers have designed a novel quintuple agonist combining GLP-1R, GIPR, and PPAR agonism to treat obesity and type 2 diabetes. The molecule, lanifibranor, shows potent effects in reducing body weight and improving hyperglycaemia in mice with obesity and insulin resistance.
A new trial has shown that a lower dose of the immunomodulatory drug ATG is safe and effective in preventing the progression of type 1 diabetes in young people. The study found that the drug was able to arrest or delay the progression of T1D at a dose as low as 0.5mg/kg, with a good safety profile.
The Ver-A-T1D trial suggests that verapamil could preserve beta-cell function in adults with newly diagnosed type 1 diabetes. The study demonstrated encouraging trends towards beta-cell preservation and well-established safety profile, but narrowly missed statistical significance.
The SURPASS-PEDS trial shows that tirzepatide significantly improves HbA1c levels, BMI, and fasting glucose in children aged 10-17 years with type 2 diabetes. The study demonstrates sustained improvements over a year-long period, making it a potential safe and efficacious treatment option for youth-onset type 2 diabetes.
A daily pill of baricitinib, a Janus kinase inhibitor, preserves insulin-producing beta cell function and slows type 1 diabetes progression in people recently diagnosed with the condition. The treatment's therapeutic effect is lost when it's stopped, justifying its testing in earlier stages to prevent or delay clinical diagnosis.
The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, with the greatest increases expected in Africa and the Middle East/North Africa. The analysis reveals substantial global inequities in diabetes care and outcomes.
A new RNA-based drug, RES-010, is designed to block an RNA molecule called miR-22, which plays a key role in obesity. The treatment has shown promising results in preclinical studies, inducing significant weight loss without regaining weight after treatment stops.
A UK Biobank study suggests that people with type 2 diabetes progress to additional chronic conditions at a faster rate than those without the condition. The study found that individuals with T2D experience a 60% higher risk of new disease diagnosis compared to those without T2D.
A new study published in Pharmaceutics found that semaglutide provides powerful protection against diabetic retinopathy, a condition that can lead to sight loss. The study suggests that GLP-1 receptor agonists enhance retinal cells' defences against damage in diabetes-like conditions.
A phase 3 trial of once-daily orforglipron found substantial weight loss in people with obesity but not type 2 diabetes. The medication improved cardiometabolic levels and was associated with significant reductions in body weight, waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol.
The European Association for the Study of Diabetes (EASD) has finalized its first evidence-based clinical practice guideline, which prioritizes assessing and managing diabetes distress among adults with type 1 and type 2 diabetes. Key recommendations include routine assessment and management of emotional burden.
A randomised trial found that regular exercise reduced inflammation and improved endothelial function, leading to lower risk of heart attack and strokes. Exercise maintained weight loss without GLP-1 receptor agonist liraglutide.
A large community-based study has found that individuals with type 2 diabetes are at a doubled risk of developing sepsis, particularly among younger adults and men. The study identified several modifiable risk factors, including smoking, high blood sugar, and complications of diabetes.
Research suggests that semaglutide, a weight loss medication, decreases intrusive thoughts about food and improves mental health in individuals with obesity. The study found that 81% of participants experienced less food noise after taking semaglutide for at least four months.